性激素结合球蛋白(SHBG)纵向变化与糖尿病发病风险:全国女性健康研究(SWAN)
研究随访2952名基线无糖尿病的绝经前或早期围绝经期女性,最多13次随访、跨度达17年,采用离散时间生存模型分析。376名女性发生糖尿病,时变SHBG每增加5单位与糖尿病风险降低10%相关(HR 0.91,95%CI 0.87-0.95),时变睾酮与风险无关。与SHBG年变化率最低四分位组相比,其余四分位组糖尿病风险均降低。
要点
- 时变SHBG每增加5单位,糖尿病风险降低10%(HR 0.91,95%CI 0.87-0.95)。
- 时变睾酮水平与糖尿病发病风险无显著关联。
- SHBG年变化率稳定至上升者较下降者糖尿病风险降低(Q2 HR 0.33,Q3 HR 0.37,Q4 HR 0.43)。
核心结论
- 围绝经期SHBG水平升高与糖尿病发病风险降低相关。
- SHBG年变化率稳定至上升较下降者独立地与糖尿病风险降低相关,提示SHBG可能通过雄激素性以外的机制影响血糖。
研究设计与样本
- 前瞻性队列研究,纳入全国女性健康研究(SWAN)中2952名基线绝经前或早期围绝经期且无糖尿病的参与者。
- SHBG、睾酮和雌二醇在最多13次随访中测定,随访跨度最长17年。
- 采用以基线为锚点的互补log-log离散时间生存模型分析。
主要发现
- 随访期间376名女性发生糖尿病。
- 时变SHBG每增加5单位与糖尿病风险降低10%相关(HR 0.91,95%CI 0.87-0.95),校正协变量及基线SHBG、睾酮和雌二醇水平。
- 时变睾酮与糖尿病风险无显著关联。
- 与SHBG年变化率最低四分位组(Q1:-92.3至-1.5 nmol/L)相比,Q2(>-1.5至-0.2 nmol/L)HR 0.33(95%CI 0.23-0.48)、Q3(>-0.2至1.3 nmol/L)HR 0.37(95%CI 0.25-0.55)、Q4(>1.3至82.0 nmol/L)HR 0.43(95%CI 0.30-0.63),均与糖尿病风险降低相关,校正协变量和基线SHBG;进一步校正睾酮和雌二醇变化率后关联持续存在。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the associations of longitudinal changes in sex hormone binding globulin (SHBG) and testosterone (T) over the menopause transition with the risk of diabetes. RESEARCH DESIGN AND METHODS: We followed 2,952 participants in the Study of Women's Health Across the Nation (SWAN) who were premenopausal or early perimenopausal and diabetes-free at baseline. SHBG,T, and estradiol (E2) levels were measured at up to 13 follow-up visits (over up to 17 years). We used complementary log-log-based discrete-time survival models anchored at baseline. RESULTS: Diabetes developed in 376 women. A 5-unit increase in time-varying SHBG was associated with a 10% reduced risk of diabetes (hazard ratio [HR] 0.91, 95% CI 0.87-0.95), adjusting for covariates, and baseline SHBG,T, and E2 levels. Time-varying T was not associated with diabetes risk. Compared with the lowest quartile for annual rate of change of SHBG since baseline (quartile 1 [Q1] -92.3 to -1.5 nmol/L), all other quartiles were associated with a decreased risk of diabetes adjusting for covariates and baseline SHBG; associations persisted after adjusting for rate of change of T and E2 (Q2 [> -1.5 to -0.2 nmol/L] HR 0.33, 95% CI 0.23-0.48; Q3 [> -0.2 to 1.3 nmol/L] HR 0.37, 95% CI 0.25-0.55; Q4 [>1.3 to 82.0 nmol/L] HR 0.43, 95% CI 0.30-0.63). CONCLUSIONS: Increasing levels of SHBG over the menopause transition were associated with a decreased risk of incident diabetes. Stable to increasing rates of change in SHBG were also independently associated with a decreased risk of diabetes compared with decreasing rates of change, suggesting SHBG may affect glucose through a mechanism beyond androgenicity.
引用
- Hedderson MM, Capra A, Lee C, et al. Longitudinal Changes in Sex Hormone Binding Globulin (SHBG) and Risk of Incident Diabetes: The Study of Women's Health Across the Nation (SWAN). Diabetes Care. 2024. PMID: 38320264. doi:10.2337/dc23-1630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。